Frankfurt
21.11.24
09:59 Uhr
2,080 Euro
-0,010
-0,48 %
-0,48 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | Advicenne achieves major milestones in the US thanks to several positive FDA opinions on ADV7103 | 301 | Business Wire | FDA agrees to submission of a marketing authorization application for ADV7103 in dRTA without further clinical studies. The positive orphan drug designation decision for ADV7103 in cystinuria... ► Artikel lesen | |
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| 18.09. | Advicenne Reports Its First Half Financial Results as of June 30, 2024, and Updates on Its Activities | 293 | Business Wire | Sibnayal® gross sales up 28% to €1.25 million including royalties paid by commercial partners (16% excluding royalties) Continued progress towards current operating breakeven Cash... ► Artikel lesen | |
| 18.07. | Advicenne Announces an 8.8% Increase in Gross Sales for H1 2024 and Provides an Update on Its Activities | 292 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 15.05. | Advicenne Announces the Approval of All Resolutions Supported by the Board of Directors at Its Combined General Meeting | 239 | Business Wire | Regulatory News:
The Combined General Meeting of shareholders of Advicenne (Euronext Growth Paris ALDVI FR0013296746) (Paris:ALDVI), a specialty pharmaceutical company dedicated to the development... ► Artikel lesen | |
| 28.03. | Advicenne: Strong improvement of 2023 results thanks to sustained commercial activity on Sibnayal | 457 | Business Wire | Sibnayal volume up 84%.
Gross sales exceed €4 million for the first time.
Sharp decrease in net loss to -7.03 M€ vs. -11.47 M€ in 2022.
Year-end cash position at €5.25 million... ► Artikel lesen | |
| 25.03. | Advicenne: FDA Grants Orphan Drug Designation to ADV7103 for the Treatment of Cystinuria. | 470 | Business Wire | After distal Renal Tubular Acidosis (dRTA) in December 2022, ADV7103 is granted "orphan drug" status in the United States in cystinuria. A long-awaited milestone for the Company and its flagship... ► Artikel lesen | |
| 23.01. | Advicenne Reports 2023 Gross Sales1 up 20% to €4.43 Million | 349 | Business Wire | PARIS--(BUSINESS WIRE)--Regulatory News:
Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative... ► Artikel lesen | |
| 28.12.23 | Advicenne Announces Its 2024 Financial Calendar | 471 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,620 | -0,21 % | Pfizer, BioNTech & Co: Trump-Ankündigung setzt Aktien unter Druck | Die Aktien von Impfstoff-Unternehmen stehen zum Wochenschluss deutlich unter Druck. Sowohl Moderna, als auch BioNTech, Pfizer und Novavax notieren im vorbörslichen US-Handel im Minus. Auch andere Pharmawerte... ► Artikel lesen | |
| ABBVIE | 159,86 | +0,45 % | European Commission Approves AbbVie's ELAHERE For Platinum-Resistant Ovarian Cancer Treatment | WASHINGTON (dpa-AFX) - AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult patients with folate receptor-alpha (FR?)... ► Artikel lesen | |
| HALEON | 4,521 | +0,49 % | Eminence Capital buys Gitlab, Charles River, exits Haleon, others in Q3 | ||
| LIGAND PHARMACEUTICALS | 106,00 | 0,00 % | ROUNDUP: Ligand Pharmaceuticals Boosts FY24 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the third quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) raised its core adjusted earnings and... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 4,045 | -0,98 % | Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline | SEATTLE and VANCOUVER, British Columbia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization... ► Artikel lesen | |
| ROYALTY PHARMA | 24,710 | -0,68 % | Dividendenbekanntmachungen (15.11.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,7 USD 0,6646 EUR ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0712 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen | |
| TG THERAPEUTICS | 31,300 | +5,81 % | TG Therapeutics, Inc.: TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500 | ||
| DR REDDYS | 13,300 | -0,75 % | DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer | ||
| EISAI | 28,490 | +0,11 % | Eisai: Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan | TOKYO, Nov 20, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the amyotrophic lateral sclerosis (ALS) treatment "Rozebalamin for Injection25 mg" (mecobalamin) has been launched in Japan... ► Artikel lesen | |
| INTRA-CELLULAR THERAPIES | 80,50 | -1,23 % | Intra-Cellular Therapies Inc.: Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance | CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase CAPLYTA's strong prescription uptake continues: Q3 2024... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,085 | +10,39 % | BETTERLIFE HLDG (06909): VERY SUBSTANTIAL ACQUISITIONS ENTERING INTO CREDITOR'S RIGHTS TRANSFER AGREEMENT AND THE DEBT SETTLEMENT AGREEMENT | ||
| VERONA PHARMA PLC ADR | 38,800 | +4,86 % | AKTIONÄR-Tipp Verona Pharma: Massives Marktpotenzial - Mega-Rally vor Fortsetzung | Der designierte US-Gesundheitsminister Robert F. Kennedy Jr. hat die Pharma- und Biotech-Branche in den zurückliegenden Handelstagen mächtig durcheinandergewirbelt. Kein Wunder, gilt der Neffe des ehemaligen... ► Artikel lesen | |
| ENTOURAGE HEALTH | 0,001 | 0,00 % | Entourage Health Corp.: Entourage Health Provides Company Update | TORONTO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE:4WE) ("Entourage" or the "Company"), a Canadian producer and distributor of award-winning cannabis... ► Artikel lesen | |
| KYOWA KIRIN | 14,700 | +1,38 % | Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias | - Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors... ► Artikel lesen | |
| IGC PHARMA | 0,314 | -2,48 % | IGC Pharma, Inc.: IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline | POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results and strategic advancements for the second fiscal quarter... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.
